Does intensified chemotherapy increase survival outcomes of osteosarcoma patients? A meta-analysis.

about

Does intensified chemotherapy increase survival outcomes of osteosarcoma patients? A meta-analysis.

Item

http://www.wikidata.org/entity/Q55439578

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Does intensified chemotherapy ...... oma patients? A meta-analysis.

@en

Does intensified chemotherapy ...... oma patients? A meta-analysis.

@nl

type

Item

label

Does intensified chemotherapy ...... oma patients? A meta-analysis.

@en

Does intensified chemotherapy ...... oma patients? A meta-analysis.

@nl

prefLabel

Does intensified chemotherapy ...... oma patients? A meta-analysis.

@en

Does intensified chemotherapy ...... oma patients? A meta-analysis.

@nl

P1476

Does intensified chemotherapy ...... oma patients? A meta-analysis.

@en

P2093

Cao Wang

http://www.w3.org/2001/XMLSchema#string

Jifei Yang

http://www.w3.org/2001/XMLSchema#string

Jingqing Yang

http://www.w3.org/2001/XMLSchema#string

Lei Han

http://www.w3.org/2001/XMLSchema#string

Na Zhao

http://www.w3.org/2001/XMLSchema#string

Santoshi Kamar

http://www.w3.org/2001/XMLSchema#string

Xiaoqian Shi

http://www.w3.org/2001/XMLSchema#string

Ya Zhang

http://www.w3.org/2001/XMLSchema#string

Yanping Duan

http://www.w3.org/2001/XMLSchema#string

Yihao Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good R

Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.

Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: results of the Institut Gustave-Roussy phase II trial

Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.

The Importance of Planned Dose of Chemotherapy on Time: Do We Need to Change Our Clinical Practice?

Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.

Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.

Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup.

Immunotherapy of cancer in 2012.

P304

54-60

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JBO.2018.04.001

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29963367

http://www.w3.org/2001/XMLSchema#string

P932

6024259

http://www.w3.org/2001/XMLSchema#string